BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28214007)

  • 1. [Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].
    Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A
    Bull Cancer; 2017 Apr; 104(4):332-343. PubMed ID: 28214007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.
    Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A
    Eur J Cancer; 2016 Apr; 57():118-26. PubMed ID: 26918737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study.
    Boudin L; Gonçalves A; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Chabannon C
    J Cancer; 2016; 7(14):2077-2084. PubMed ID: 27877223
    [No Abstract]   [Full Text] [Related]  

  • 4. Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
    Boudin L; Gonçalves A; Sabatier R; Moretta J; Sfumato P; Asseeva P; Livon D; Bertucci F; Extra JM; Tarpin C; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Sobol H; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Viens P; Eisinger F; Chabannon C
    Bone Marrow Transplant; 2016 Aug; 51(8):1082-6. PubMed ID: 27042835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
    Shi Y; Pan F; Han X
    Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
    Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
    Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
    VanderWalde A; Ye W; Frankel P; Asuncion D; Leong L; Luu T; Morgan R; Twardowski P; Koczywas M; Pezner R; Paz IB; Margolin K; Wong J; Doroshow JH; Forman S; Shibata S; Somlo G
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1273-80. PubMed ID: 22306735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry.
    Pedrazzoli P; Martinelli G; Gianni AM; Da Prada GA; Ballestrero A; Rosti G; Frassineti GL; Aieta M; Secondino S; Cinieri S; Fedele R; Bengala C; Bregni M; Grasso D; De Giorgi U; Lanza F; Castagna L; Bruno B; Martino M;
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):501-6. PubMed ID: 24374214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
    Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
    Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
    Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
    J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
    Jin X; Jiang YZ; Chen S; Yu KD; Shao ZM; Di GH
    Oncotarget; 2015 Apr; 6(11):9600-11. PubMed ID: 25826079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG.
    Kuroi K; Toi M; Ohno S; Nakamura S; Iwata H; Masuda N; Sato N; Tsuda H; Kurosumi M; Akiyama F
    Breast Cancer; 2015 Sep; 22(5):486-95. PubMed ID: 24338638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
    Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U
    J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
    Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ
    Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
    J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma.
    Arun B; Slack R; Gehan E; Spitzer T; Meehan KR
    Cancer; 1999 Jan; 85(1):93-9. PubMed ID: 9921979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.